公开(公告)号：US20230212653A1

公开(公告)日：2023-07-06

申请号：US18076279

申请日：2022-12-06

Applicant: Myriad Genetics, Inc.

Inventor： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/6827 ,  A61K33/243 ,  C12Q1/6886 ,  G16B20/20

CPC classification number: C12Q1/6827 ,  A61K33/243 ,  C12Q1/6886 ,  G16B20/20 ,  C12Q2600/154 ,  C12Q2600/156

Abstract: Provided herein are methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

公开(公告)号：US11225685B2

公开(公告)日：2022-01-18

申请号：US16815963

申请日：2020-03-11

Applicant: MYRIAD GENETICS, INC.

Inventor： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/6827 ,  G16B30/00 ,  C12Q1/6858 ,  C12Q1/6874 ,  C12Q1/6883

Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

公开(公告)号：US20170137890A1

公开(公告)日：2017-05-18

申请号：US15331076

申请日：2016-10-21

Applicant: Myriad Genetics, Inc.

Inventor： Jerry Lanchbury ,  Alexander Gutin ,  Darl Flake

IPC: C12Q1/68 ,  G06F19/24

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N2800/54 ,  G16B20/00 ,  G16B25/00 ,  G16B40/00

Abstract: The disclosure provides for molecular classification of disease and, particularly, molecular markers for breast cancer prognosis and methods and systems of use thereof.

公开(公告)号：US20170022569A1

公开(公告)日：2017-01-26

申请号：US15192497

申请日：2016-06-24

Applicant: Myriad Genetics, Inc.

Inventor： Victor Abkevich ,  Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/68 ,  A61K31/282 ,  A61K33/24

CPC classification number: C12Q1/6886 ,  A61K31/282 ,  A61K33/24 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Abstract translation: 本文件提供了评估样品（例如癌细胞）中存在杂合性（LOH）特征丧失的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否包含LOH标记的方法和材料。 还提供了用于鉴别具有同源性定向修复（HDR）缺陷的细胞（例如癌细胞）的材料和方法以及用于鉴定可能对特定癌症治疗方案作出反应的癌症患者的材料和方法。

公开(公告)号：US20160160294A1

公开(公告)日：2016-06-09

申请号：US14962588

申请日：2015-12-08

Applicant: Tesaro ,  Myriad Genetics, Inc.

Inventor： Keith Wilcoxen ,  Alexander Gutin ,  Kirsten Timms ,  Victor Abkevich ,  Yan Wang ,  Jerry Lanchbury

IPC: C12Q1/68 ,  A61K31/454

CPC classification number: C12Q1/6886 ,  A61K31/454 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided.

Abstract translation: 本文件提供了评估样品（例如癌细胞）是否存在同源重组缺陷（HRD）或HRD特征以预测对尼拉帕布反应的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否含有HRD特征以预测对尼拉帕布的反应的方法和材料。

公开(公告)号：US20160145681A1

公开(公告)日：2016-05-26

申请号：US15010721

申请日：2016-01-29

Applicant: Myriad Genetics, Inc.

Inventor： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/68

CPC classification number: C12Q1/6827 ,  C12Q1/6858 ,  C12Q1/6874 ,  C12Q1/6883 ,  G06F19/22 ,  C12Q2535/122 ,  C12Q2537/143

Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

Abstract translation: 提供了使用核酸测序检测等位基因不平衡的方法和系统。

公开(公告)号：US20240301500A1

公开(公告)日：2024-09-12

申请号：US18277554

申请日：2022-02-24

Applicant: MYRIAD GENETICS, INC.

Inventor： Elisha Hughes ,  Alexander Gutin ,  Jerry Lanchbury ,  Susanne Wagner

IPC: C12Q1/6886 ,  C12Q1/6874

CPC classification number: C12Q1/6886 ,  C12Q1/6874 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Provided herein are methods for assessing a risk of a trait in a subject, by selecting a plurality of ancestry-informative SNP markers based on objective design criteria, measuring a genotype of the subject, obtaining trait-associated SNP markers, and calculating a global polygenic risk score for the risk of the trait in the subject based on the plurality of ancestry-informative SNP markers and the trait-associated SNP markers. The trait can be risk of cancer. Also provided are methods for assessing ancestry of a subject.

公开(公告)号：US20230260658A1

公开(公告)日：2023-08-17

申请号：US17920013

申请日：2021-04-16

Applicant: Myriad Genetics, Inc.

Inventor： Dmitry Pruss ,  Alexander Gutin ,  Elisha Hughes ,  Jerry Lanchbury

IPC: G16H50/30 ,  G16B20/20 ,  G16B20/40 ,  G16B40/00

CPC classification number: G16H50/30 ,  G16B20/20 ,  G16B20/40 ,  G16B40/00

Abstract: Provided herein are methods for determining polygenic traits and risks for medical use, such as cancer traits and risks, as well as treating diseases for which risk is identified and/or assessed. Methods of this invention can provide a polygenic score which takes into account local ancestry through the ancestral origin of the alleles of risk loci. A polygenic score can provide surprisingly increased accuracy in determining polygenic traits and risks for ancestrally admixed populations.

公开(公告)号：US20230170045A1

公开(公告)日：2023-06-01

申请号：US17920012

申请日：2021-04-16

Applicant: Myriad Genetics, Inc.

Inventor： Shannon Gallagher ,  Elisha Hughes ,  Alexander Gutin ,  Jerry Lanchbury

IPC: G16B20/20 ,  C12Q1/6886 ,  G16H50/30

CPC classification number: G16B20/20 ,  C12Q1/6886 ,  G16H50/30 ,  C12Q2600/156

Abstract: Provided herein are methods for determining a polygenic risk score and breast cancer estimated risk for medical use, as well as for treating breast cancer. Methods of this invention can provide a polygenic risk score which takes into account a plurality of breast cancer associated SNP markers. Also provide is a comprehensive breast cancer risk estimation with increased accuracy.

公开(公告)号：US20230111438A1

公开(公告)日：2023-04-13

申请号：US18081586

申请日：2022-12-14

Applicant: Myriad Genetics, Inc.

Inventor： Victor Abkevich ,  Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/6886 ,  G16B20/20 ,  G16B20/10 ,  A61K33/243 ,  A61K31/282

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.